Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Justin Klee

Joshua Cohen

Amylyx Pharmaceuticals, Inc.

Alys Pharmaceuticals is an R&D anchored immuno-dermatology focused company that aims to redefine the treatment landscape for dermatologic conditions with transformative solutions.

Alys Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz 

Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

The ALS Association

ALS Finding a Cure

Lysosomal Therapeutics

Morningside Group

ALS Investment Fund

Morningside Venture Investments

DRADS Capital

Woodline Partners

Marshall Wace

Perceptive Advisors

Polaris Founders Capital

Tybourne Capital Management

Verition Fund Management

683 CAPITAL

aMoon Fund

Belinda Termeer

Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com. 

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.

Today we announced the first participant dosed in the largest #progressivesupranuclearpalsy study to date. This Phase 3 #clinicaltrial for the treatment of #PSP will enroll approximately 600 participants across ~100 sites in the U.S., Canada, the EU, the UK, and Japan.
Read more: https://lnkd.in/enCfTTKU 

As 2023 draws to a close, we’re also reflecting on 10 years of Amylyx. We’d like to show our gratitude to the incredible determination of the #ALS and #neurodegenerative community, as well as our extraordinary global colleagues who show up every day with the shared mission of one day ending the suffering caused by neurodegenerative diseases.

At Amylyx, we’ve created a culture that uses unconventional thinking for unsolved problems. We learn from one another through our collective experience, and we share a connection in our common purpose. 
Does this sound like you? 
See our current openings: https://lnkd.in/eDq_3vK4 

Metric
Company Name	Amylyx Pharmaceuticals, Inc.	Alys Pharmaceuticals
Symbol	AMLX
MSH ID	COM:AMYLYX	COM:ALYSPHARMA
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	US	US
Stage
Employee Count	384
Website	amylyx.com	alyspharma.com
LinkedIn	amylyx
Founders

Metric
Market Cap	140.77M
Enterprise Value
Monthly Web Traffic	9.71K
Web Traffic Growth	-0.23
Valuation
Raised Capital

Metric
Revenue	380.79M
Revenue (LTM)
Revenue (NTM)
Gross Profit	355.35M
EBITDA	39.89M
Operating Income	38.80M
Net Income	49.27M
EPS	0.73
Diluted EPS	0.70
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.93
Operating Profit Margin	0.10
EBITDA Margin	0.10
Net Profit Margin	0.13
Return on Equity	0.12
Return on Assets	0.10
Return on Capital Employed	0.09

COM:AMYLYX

Amylyx Pharmaceuticals, Inc.

Last Close

5.19

22/11 21:00

Market Cap

140.77M

Beta: -

Volume Today

831.95K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	566.01
P/B Ratio	2.48
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.09
EV Multiple	9.04

Metric
Days Sales Outstanding	36.41
Days Payables Outstanding	123.02
Days Inventory Outstanding	549.82
Operating Cycle	588.21
Cash Conversion Cycle	271.70
Asset Turnover	0.95

Metric
Operating Cash Flow	11.92M
Free Cash Flow	10.68M
Cash Flow to Debt	4.47
Operating Cash Flow/Sales	0.04
Free Cash Flow Yield	-0.05

Metric
Cash & Equivalents	170.20M
Accounts Receivable	-24.74M
Inventory	38.32M
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	9.52
Quick Ratio	5.01

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11
R&D to Revenue	0.36
SG&A to Revenue	0.34